Atay Oguzhan sold $261K of BLLN (indirect holdings)

Atay Oguzhan (Chairman and CEO) sold 2,667 indirectly-held shares of BillionToOne, Inc. (BLLN) at $98.00 ($0.26M total) on 2026-10-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Oct 16, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 11:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The transaction modestly reduces insider ownership and may be interpreted as a slight negative signal, but the amount is small relative to the company's market cap.

02

Market read

A modest insider sell by the CEO, likely to cause limited short‑term price pressure.

03

What to watch

Potential upcoming financing needs or personal tax planning may drive the sale.

Relevance 3/10Novelty 3/10Timing: after‑hours filing

Background

Form 4 filings disclose insider transactions; this filing reports a CEO's open‑market sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

Chairman and CEO sold 2,667 shares for $261,366 via a 10b5‑1 plan, reducing his stake to 149,168 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell

Evidence & confidence

Sale size is modest ($261K) but involves the CEO, which can influence sentiment.

Market effects

Minimal impact on the broader biotech sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • BillionToOne, Inc.

    US‑listed biotech firm (ticker BLLN).

  • Atay Oguzhan

    Chairman and CEO of BillionToOne, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.